Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure ...

Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology ...

Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or ...

TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, ...

Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded ...

A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.

Study to test RC220 alongside standard-of-care osimertinib to prevent or delay treatment resistance. ... Read More The post ...

Immutep (IMMP) stock plummeted 80% after the company halted its Phase III NSCLC trial for futility, triggering analyst downgrades and massive selling.

The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond ...

A new leak suggests that Vivo could be jumping on the big-battery bandwagon with an upcoming smartphone. According to Weibo tipster Digital Chat Station, Vivo is currently testing a new phone equipped ...